Welcome to our dedicated page for Oscar Health news (Ticker: OSCR), a resource for investors and traders seeking the latest updates and insights on Oscar Health stock.
Oscar Health, Inc. reports news on its healthcare technology business, which uses a full-stack platform to offer Individual & Family health plans, ICHRA solutions, +Oscar technology services and the Lucie Health Marketplace. Company updates commonly cover quarterly financial results, medical loss ratio and expense metrics, guidance, membership trends and product expansion in the individual health insurance market.
Oscar Health announcements also include marketplace and plan launches, broker and employer-facing healthcare shopping tools, technology features, capital-structure activity and board governance changes. The company’s recurring news themes connect its insurance products, member experience and healthcare technology services to developments in ACA exchange markets and consumer-directed coverage.
Oscar Health, Inc. (NYSE: OSCR), a prominent healthcare technology company, is set to release its financial results for the second quarter of 2024 on Wednesday, August 7, 2024, before the market opens. Management will hold a conference call to discuss the results starting at 8:00 AM (ET). The live call can be accessed by dialing (888) 596-4244 using Conference ID 776-8132, and a webcast will be available. The call will also be archived on Oscar’s investor relations website for 90 days following the event.
Oscar Health, a healthcare technology company, will participate in the BofA Securities 2024 Global Health Care Conference. Chief Financial Officer, Scott Blackley, will present a business update on May 15, 2024. Interested parties can listen to the webcast on Oscar's investor relations website.
Oscar Health, Inc. announced its financial results for the first quarter of 2024, reporting total revenue of $2.1 billion, a 46% increase year-over-year. The company achieved positive net income of $177.4 million, with diluted earnings per share of $0.62. Key metrics like Medical Loss Ratio and SG&A Expense Ratio showed significant improvements. Adjusted EBITDA improved by $168.2 million year-over-year. The company reaffirmed its full-year 2024 outlook across all metrics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.